Trisha Shetty (Editor)

Tibotec

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Founder
  
Rudi Pauwels

Parent organization
  
Johnson & Johnson

Founded
  
1994

Tibotec httpsuploadwikimediaorgwikipediacommonsthu

Headquarters
  
Yardley, Pennsylvania, United States

Tibotec was a pharmaceutical company with a focus on research and development for the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by and Johnson & Johnson and merged into its Janssen Pharmaceutica division in 2002.

Contents

History

In 1994, Rudi Pauwels of the Rega Institute for Medical Research founded Tibotec, together with his wife Carine Claeys, and their first co-workers Marie-Pierre de Béthune, Kurt Hertogs, and Hilde Azijn. In 1995 Paul Stoffels (Janssen Pharmaceutica) joined Tibotec. The company was acquired by Johnson & Johnson in April 2002. The name of the company is derived from the tetrahydro-imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) compounds discovered at the Rega Institute for Medical Research (Belgium).

Drugs

  • Darunavir (TMC114, tradename Prezista), a protease inhibitor
  • Etravirine (TMC125, tradename Intelence), a non-nucleoside reverse transcriptase inhibitor (NNRTI)
  • Bedaquiline (TMC207/R207910, tradename Sirturo), an diarylquinoline anti-tuberculosis drug
  • Rilpivirine (TMC278, tradename Edurant), an NNRTI
  • Simeprevir (TMC435, tradename Olysio), an HCV NS3/4A protease inhibitor for treatment of chronic hepatitis C in combination with pegylated interferon/ribavirin or with other direct-acting anti-HCV agents.
  • Dapivirine (TMC120), an NNRTI licensed to the International Partnership for Microbicides for its development as a vaginal microbicide in March 2004.

    • References

    Tibotec Wikipedia
    (Text) CC BY-SA


    Similar Topics